Enjoy complimentary customisation on priority with our Enterprise License!
The Specialty Pharmaceuticals Market size is estimated to grow by USD 331.12 billion at a CAGR of 12.59% between 2022 and 2027.
The increasing demand for R&D due to government healthcare expenditure is driving market growth. Small laboratory studies and large-scale production of specialty pharmaceutical products require the ability to produce an enriched sample of small molecules, cells, proteins, nucleic acids, or clean solutions. Adhering to regulations regarding the purity and consistency of specialty pharmaceutical products demands a well-structured plan and a vast amount of R&D investment. For example, certain pharmaceutical companies spend approximately 15%-20% of total revenue on R&D activities. This is likely to further boost the demand for specialty pharmaceutical products resulting in manufacturers coming up with innovative and advanced specialty pharmaceuticals to cater to the demand. Hence, the market is likely to witness further growth during the forecast period.
Technavio has segmented the market into Application, Distribution Channel, and Geography.
It also includes an in-depth analysis of drivers, trends, and challenges.
To learn more about this report, Request Free Sample
Oncology segment
The market share growth by the oncology segment will be significant during the forecast period. They are primarily used for cancer treatment by limiting the growth and further spread of cancer cells. Several types of oncology drugs exist such as chemotherapy, targeted therapy, immunotherapy, and hormone therapy.
Get a glance at the market contribution of various segments View a PDF Sample
The oncology segment was valued at USD 73.17 billion in 2017. This type of drug, dosage, and treatment plan depends on the type and stage of cancer, the overall health and medical history of the patient, and the potential side effects of the treatment. They are a vital component of cancer treatment and can have resulted in higher survival rates and improved quality of life for cancer patients. Hence the necessity of this segment in cancer treatment is likely to result in further growth of the market during the forecast period.
Offline segment
The offline distribution segment of the global specialty pharmaceuticals market refers to the traditional distribution channels through which specialty pharmaceuticals are sold and supplied outside the online marketplace. It includes channels such as physical retail stores, pharmacies, hospitals, clinics, and other healthcare facilities and caters to patients who choose to purchase medications from brick-and-mortar establishments. They ensure patients have greater access and provide direct interaction with healthcare providers for personalized guidance and recommendations regarding drug dosage, and potential side effects. Hence this segment of the market is vital in ensuring access to medications for patients worldwide, which is likely to influence further market growth during the forecast period.
For more insights about the market share of various regions View PDF Sample now!
North America is estimated to contribute 53% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. In the region, the US and Canada are the largest markets primarily due to the increasing government expenditure into supporting cancer treatment R&D and the increasing prevalence of cancer. For instance, the Fiscal Year 2021 (FY21) Omnibus Appropriation Bill was signed in December 2020, allocating USD 6.56 billion for the National Cancer Institute (NCI). Moreover, other factors such as advanced technology, a well-established healthcare infrastructure, and numerous specialty pharmaceutical manufacturers are likely to further boost the growth of the regional market during the forecast period.
The COVID-19 outbreak had a negative impact on the regional market in 2020-2021. However, large-scale vaccination drives in 2020 and the easing of restrictions resulted in the resumption of the operations of pharmaceutical manufacturing and logistics units. Additionally, the approval of various drugs such as the US FDA-approved TheraSphere Y-90 glass microspheres manufactured by Boston Scientific Corp for the treatment of hepatocellular carcinoma (HCC) patients is also likely to boost the growth of the market during the forecast period.
Buy Now Full Report and Discover More
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 21 market vendors, including:
AbbVie Inc. - The company offers specialty pharmaceuticals for Immunology, Neuroscience, and Oncology.
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges.
The increasing geriatric population is a key trend in the market. The growing geriatric population increases the prevalence of chronic illnesses resulting in higher demand for various therapeutic drugs for their effective treatment. For them, to have a high quality of life, they need frequent, continuous medical treatment by skilled public healthcare professionals. The number of US adults older than 65 years is predicted to double by 2030 according to Centers for Disease Control and Prevention (CDC) statistics.
Hence, this will increase the burden on national healthcare systems to provide more effective services to treat age-related conditions and diseases, which requires greater healthcare expenditure. The overall national healthcare spending is estimated to increase by 25% by 2030 as per CDC statistics. To treat chronic diseases, national healthcare regulatory bodies are promoting the usage of specialty pharmaceuticals. This is resulting in a higher number of emerging specialty pharmaceutical manufacturers in the US and Europe and is likely to boost the growth of the market during the forecast period.
Stringent regulations are challenging market growth. Regulatory bodies meticulously examine drug-related data before medication approval, especially for specialty pharmaceuticals. The US Food and Drug Administration is an important regulatory body that ensures the safety, efficacy, pharmacological data, pharmacodynamic effects, and drug interactions. If it doesn't meet the required standards the manufacturer will receive a complete response letter (CRL) or could even face complete rejection
Moreover, on receiving a CRL, a drug manufacturer must reveal more data regarding the drug which might even necessitate additional clinical trials. This will further increase R&D expenditure due to which some pharmaceutical companies might withdraw their applications altogether. Hence such factors are likely to pose a hindrance to the growth of the market during the forecast period.
Buy Now Full Report and Discover More
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Specialty Pharmaceuticals Market Customer Landscape
The specialty pharmaceuticals market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Specialty Pharmaceuticals Market Scope |
|
Report Coverage |
Details |
Page number |
160 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 12.59% |
Market growth 2023-2027 |
USD 331.12 billion |
Market structure |
Fragmented |
YoY growth 2022-2023(%) |
11.05 |
Regional analysis |
North America, Europe, Asia, and the Rest of the World (ROW) |
Performing market contribution |
North America at 53% |
Key countries |
US, Germany, UK, China, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
AbbVie Inc., Amgen Inc., Biodexa Pharmaceuticals PLC, Bristol Myers Squibb Co., Cigna Corp., CVS Health Corp., Endo International Plc, F. Hoffmann La Roche Ltd., Gilead Sciences Inc., Humana Inc., Hyphens Pharma Pte Ltd., Johnson and Johnson Services Inc., Kroger Co., McKesson Corp., Merck and Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UnitedHealth Group Inc., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
View Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Application
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.